Cargando…
MAP3K19 Is a Novel Regulator of TGF-β Signaling That Impacts Bleomycin-Induced Lung Injury and Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) is a progressive, debilitating disease for which two medications, pirfenidone and nintedanib, have only recently been approved for treatment. The cytokine TGF-β has been shown to be a central mediator in the disease process. We investigated the role of a novel kin...
Autores principales: | Boehme, Stefen A., Franz-Bacon, Karin, DiTirro, Danielle N., Ly, Tai Wei, Bacon, Kevin B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4856290/ https://www.ncbi.nlm.nih.gov/pubmed/27144281 http://dx.doi.org/10.1371/journal.pone.0154874 |
Ejemplares similares
-
MAP3K19 Is Overexpressed in COPD and Is a Central Mediator of Cigarette Smoke-Induced Pulmonary Inflammation and Lower Airway Destruction
por: Boehme, Stefen A., et al.
Publicado: (2016) -
Targeting MAP3K19 prevents human lung myofibroblast activation both in vitro and in a humanized SCID model of idiopathic pulmonary fibrosis
por: Jones, Isabelle C., et al.
Publicado: (2019) -
Regorafenib-Attenuated, Bleomycin-Induced Pulmonary Fibrosis by Inhibiting the TGF-β1 Signaling Pathway
por: Li, Xiaohe, et al.
Publicado: (2021) -
Polydatin prevents bleomycin-induced pulmonary fibrosis by inhibiting the TGF-β/Smad/ERK signaling pathway
por: Liu, Yan-Lu, et al.
Publicado: (2020) -
Curdione ameliorates bleomycin-induced pulmonary fibrosis by repressing TGF-β-induced fibroblast to myofibroblast differentiation
por: Liu, Peng, et al.
Publicado: (2020)